51. Hollander E, Wong CM: Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56(suppl 4):3– 6
52. McElroy SL, Phillips KA, Keck PE Jr: Obsessive compulsive spectrum disorder. J Clin Psychiatry 1994; 55(October, suppl):33–51
53. Meyer V: Modification of expectations in cases with obsessional rituals. Behav Res Ther 1966; 4:273–280
54. Abramowitz JS: Does cognitive-behavioral therapy cure obsessive-compulsive disorder? A meta-analytic evaluation of clinical significance. Behavior Therapy 1998; 29:355
55. Eddy KT, Dutra L, Bradley R, Westen D: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004; 24:1011–1030
56. Fisher PL, Wells A: How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Res Ther 2005; 43:1543–1558
57. Cottraux J, Note I, Yao SN, Lafont S, Note B, Mollard E, Bouvard M, Sauteraud A, Bourgeois M, Dartigues JF: A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother Psychosom 2001; 70:288–297
58. Whittal ML, Thordarson DS, McLean PD: Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs exposure and response prevention. Behav Res Ther 2005; 43:1559–1576
59. Freeston MH, Rheaume J, Ladouceur R: Correcting faulty appraisals of obsessional thoughts. Behav Res Ther 1996; 34:433–446
60. Cottraux J, Bouvard MA, Milliery M: Combining pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 2005; 34:185–192
61. Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB: Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive- compulsive disorder. CNS Spectr 2003; 8:363–371, 381
62. Rothbaum BO, Shahar F: Behavioral treatment of obsessive- compulsive disorder in a naturalistic setting. Cognitive and Behavioural Practice 2000; 7:262–270
63. Warren R, Thomas JC: Cognitive-behavior therapy of obsessive-compulsive disorder in private practice: an effectiveness study. J Anxiety Disord 2001; 15:277–285
64. Abramowitz JS, Franklin ME, Zoellner LA, DiBernardo CL: Treatment compliance and outcome in obsessive-compulsive disorder. Behav Modif 2002; 26:447–463
65. De Araujo LA, Ito LM, Marks IM: Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder. Br J Psychiatry 1996; 169:747–752
66. Marks IM. Review of behavioral psychotherapy. I: Obsessive-Compulsive Disorder. Am J Psychiatry 1981; 138:584-92.
67. Roper G, Rachman S, Marks I: Passive and participant modelling in exposure treatment of obsessive-compulsive neurotics. Behav Res Ther 1975; 13:271–279
68. Lindsay M, Crino R, Andrews G: Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry 1997; 171:135–139
69. Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A, Isomura K, Kato N, Yoshioka K, Kawamoto M: A randomized controlled trial of Japanese patients with obsessive-compulsive disorder—effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom 2005; 74:269–276
70. Yaryura-Tobias JA, Neziroglu F. Biobehavioral Treatment of Obsessive- Compulsive Spectrum Disorder. New York. Eds Norton, 1997.
71. Montgomery SA. Psychopharmacology of Obsessive-Compulsive Disorder. CNS Spectrums 1998; 3, 5(suppl 1):33-37.
72. De Araujo LA, Ito LM, Marks IM: Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder. Br J Psychiatry 1996; 169:747–752
73. Kozak MJ, Foa EB: Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder. Behav Res Ther 1994; 32:343–353
74. Yaryura-Tobias JA. The Unified Theoryvof Obsessive-Compulsive Disorder. CNS Spectrums 1998; 3, 7:51-60.
75. Expert Consensus Panel: Treatment of obsessivecompulsive disorder. The Expert Consensus Panel for Obsessive-Compulsive Disorder. J Clin Psychiatry 1997; 58(suppl 4):2–72
76. Ruegg RG, Evans DL, Comer WS. Lithium augments Fluoxetine treatments of obsessive-compulsive disorder. Lithium 1992; 3(1):69-71
77. Ackerman DL, Greenland S: Multivariate metaanalysis of controlled drug studies for obsessivecompulsive disorder. J Clin Psychopharmacol 2002; 22:309–317
78. Neziroglu F, Henriksen J, Yaryura-Tobias JA: Review of psychotherapy of obsessive-compulsive disorder: established facts and advances between 1995–2005. Psychiatr Clin North Am 2006; 29:585–604
79. Neziroglu F. Tratamiento del trastorno obsesivo compulsivo y otros trastornos asociados. VERTEX Rev. Arg. de Psiquiat.1999, Vol. X:207-215.
80. Denys D, Burger H, van Megen H, de Geus F, Westenberg H: A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2003; 18:315–322
81. Simpson HB, Huppert JD, Petkova E, et al. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 269-276.
82. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2005; 63: 796-801.
83. Pigott TA, L´Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipraminetreated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11-18.
84. Maina G, Albert U, Ziero S, et al. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?. Int Clin Psychopharmacol 2003; 18: 23-2
85. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 368-373
86. Van Renynghe de Voxvrie G. Use of anafranil (G 34586) in obsessive neuroses. Acta Neurol Belg.1968;68:787-792.
87. Joel SW. Twenty month study of ipronaiazid therapy. Dis Nerv Syst. 1959;20:14.
88. De Veaugh-Geiss J, Katz R, Landau et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder; the clomipramine collaborative study group. Arch Gen Psychiatry. 1991;48:730-738.
89. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms (letter). J Clin Psychopharmacol 1994; 14: 358-359.
90. Dryden-Edwards RC, Reiss AL. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J. Child Adolescent Psychopharmacology 1996; 6(2): 139-145.
91. Poyurovsky M, Hermesh H, Weizman A. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptomes in schizophrenic patients. Clin Neuropharmacol 1996; 19: 305-313.
92. Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 1998; 155: 855.
93. Mottard JP, Sablonniere JF. Olanzapine induced obsessive-compulsive disorder. A, J Psychiaty 1999; 156: 799-800.
94. McDougle CJ, Goodman WK, Price L et al. Neuroleptic addition in fluvoxamine-refractary obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 652-654.
95. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56(11): 526-528.
96. Ravizza L, Barzega G, Bellino S et al. Therapeutic effect and safety of adjuntive risperidone in refractory obsessive-compulsive disorder (OCD). Psychoparmacol Bull 1996; 32(4): 677-682.
97. Saxena S, Wang D, Bystritsy A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57(7): 303-306.
98. Salmerón JM, Alcántara AG, Barcia D. Combinación de risperidona y antidepresivos serotoninérgicos en el trastorno obsesivo-compulsivo. Actas Luso-Esp Neurol Psiquiatr 1998; 26(6): 399-402.
99. Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-conpulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatr Clin Neurosci 2000; 54(5): 599-601.
100. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000; 15(5): 297-301.
101. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotnonin reuptake inhibitor treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 115-123.
102. Bach M, Aigner M, Lenz G. Ritanserin as adjunt to fluoxetine treatment of OCD patients with psychotic features. Pharmacopsychiatry 1997; 30(1):28-29.
103. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801
104. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801.
105. Potenza MN, Wasylink S, Loughurst JG, et al. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18: 453-454.
106. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156 (11); 1834-1835.
107. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999; 60(8): 524-527.
108. Koran LM, Ringold AL, Elliot MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(7): 514-517.
109. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12 week open trial. Psychiatry Res 2000; 96: 91-98.
110. McDougle CJ, Goodman WK, Leckman J et al. Haloperidol addition in fluvoxamine refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994: 51; 302-308
111. Bach M, Aigner M, Lenz G. Ritanserin as adjunt to fluoxetine treatment of OCD patients with psychotic features. Pharmacopsychiatry 1997; 30(1):28-29.
112. Rauch SL, Jenike MA. Management of treatment-resistant obsessive-compulsive disorder: concepts and strategies. En Hollander E, Zohar J, Marazziti D, Olivier B (dirs.). Current insights in Obsessive Compulsive Disorder. John Wiley & Sons, Chichester, 1994.
113. Pato M, Pigott T, Hill J, et al. Controlled comparison 114. Greist J, Jefferson J. Pharmacotherapy for obsessivecompulsive disorder. Br J Psychiatry 1998;173(suppl 35):64-70
115. Hollander E, Pallanti S. Current and experimental therapeutics of OCD. En Neuropsychopharmacology, The Fifth Generation of Progress. Davis KL, Charney D,
Coyle JT, Nemeroff Ch editors. 5º ed. Lipincott Williams & Wilkins: Philadelphia;2002. p. 1647-64.
116. Pallanti S, Hollander E, Goodman WK. A Qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004;65(suppl 14):6-10.
117. Janardhan Reddy YC; D'Souza MS; Shetti CP. An 11-to 13-year follow-up study with obsessive-compulsive disorder. J Clin Psychiatry 2005;66(6):744-9.
118. Davidson J, Connor O. Treatment of Anxiety Disorders. En: Textbook of Psychopharmacology, Third Edition. Schatzberg, A. F; Nemeroff, Ch. B editors. 3º ed. American Psychiatric Press: Washington DC;2004. p. 913-34.
119. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(suppl 5):7-12.
120. Keuneman JR, Pokos V, Weerasundera R. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 2005;39(5):336-43.
121. Denys D, Zohar J, Westenberg H. The Role of dopamine in obsessive-compulsive disosrder: preclinical and clinical evidence. J Clin Psychiatry 2004;65(suppl.14):11-17.
122. Li X, May RS, Tolbert LC. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66(6):736-43.
123. Pigott, T.A. y Seay, S. (2000). Pharmacotherapy of obsessive-compulsive disorder: Overview and treatment-refractory strategies. En Goodman.